Peptide, collagen supplements surge in India as experts flag thin evidence behind the hype
Brands like OZiva, HK Vitals and Isopure ride a booming nutraceuticals wave, but experts warn marketing outpaces proof. FMCG players reformulate for clean-label nutrition while regulators face calls to tighten labelling and quality oversight.
What happened
Peptide and collagen supplements are surging in India across brands like OZiva, HK Vitals and Isopure, but experts warn evidence lags marketing hype. FMCG
Key facts
- 70% cancer rise by 2050
- 2026 Market Decipher report
Why this matters
Acquisition targets like OZiva and HK Vitals carry category tailwinds, but diligence must weigh substantiation gaps and labelling exposure against fast-scaling revenue.
What to watch
- FSSAI draft guidelines or advisories on nutraceutical labelling and health claims
- Adverse test reports from consumer bodies or lab audits on marketed products
- Major FMCG earnings calls flagging nutraceutical category investment or M&A
- Viral influencer/expert debunking content shifting sentiment metrics
- Import/quality flags on collagen sourcing (bovine/marine) affecting supply
- Audit private-label and partner supplement portfolios for claim substantiation risk ahead of likely FSSAI scrutiny
- Prioritize clinically-backed SKUs with third-party testing certification as trust differentiators
- Shift marketing spend toward transparency and ingredient-sourcing narratives over efficacy hype
- Explore partnerships or acquisition of evidence-forward D2C brands to capture premium demand
- Build a rapid-response protocol for social-media debunking cycles targeting collagen/peptide claims